Medical drug program updates
Updates to existing prior authorization programs | ||
Drug(s) | Effective date | Policy & additional Information |
Xolair (omalizumab) | 8/1/2024 | |
Breyanzi (lisocabtagene maraleucel) |
6/1/2024 | Breyanzi (lisocabtagene maraleucel)
Breyanzi (HCPCS Q2054) will now be covered, with prior authorization, for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). |